{"id":32797,"date":"2020-07-30T15:10:09","date_gmt":"2020-07-30T14:10:09","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=32797"},"modified":"2023-04-29T21:56:27","modified_gmt":"2023-04-29T20:56:27","slug":"fiona-greer","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2018-speakers\/fiona-greer\/","title":{"rendered":"Fiona Greer"},"content":{"rendered":"
\n\n\t

Fiona Greer<\/h2>\n

Life Sciences Global Director, Biopharma Services Development at SGS<\/h4>\n\t

Dr Fiona Greer was a founding Director of M-Scan (Mass Spectrometry Consultants and Analysts), contract analytical laboratories specializing in biopharmaceutical characterization. Following acquisition in 2010, she is now Global Director, Biopharma Services Development, SGS Life Sciences.<\/p>\n

Following a Ph.D. in Protein Biochemistry from Aberdeen University (1984) she joined M-Scan to establish and direct biologics characterization services. Here, she pioneered and applied new developments in Mass Spectrometry for structural analysis and sequencing of proteins and carbohydrates resulting in numerous publications and patents. She was instrumental in expansion of the group, establishing a US facility where she was appointed VP.<\/p>\n

With over 35 years experience in glycoprotein analysis using instrumental techniques, she has been involved with a diverse range of biotechnology products, both novel and biosimilar and consults to companies throughout the world. She is regularly invited to give presentations and workshops at international meetings. In 2016 she was named in the Medicine Makers “Power List – Top 100 influencers”.<\/p>\n\t\t\t\t\t\t\t\"Fiona_Greer_BioTech_Pharma_Porto_profile\"\t\t\t\t\t\t\t\n

\n\tTitle: Critical Analytical Characterization Steps for Biosimilarity Assessment\n\t<\/h3>\n\t